Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Handa Pharmaceuticals Inc banner
H

Handa Pharmaceuticals Inc
TPEX:6620

Watchlist Manager
Handa Pharmaceuticals Inc
TPEX:6620
Watchlist
Price: 75 TWD -1.06% Market Closed
Market Cap: NT$12.7B
Write Note Create Alert Ask AI

Wall St Price Targets

Price Targets Summary
Handa Pharmaceuticals Inc

Wall Street analysts forecast Handa Pharmaceuticals Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Handa Pharmaceuticals Inc is 102 TWD with a low forecast of 101 TWD and a high forecast of 105 TWD.

Lowest Forecast
Wall Street Target
NT$101
35% Upside
Average Forecast
Wall Street Target
NT$102
36% Upside
Highest Forecast
Wall Street Target
NT$105
40% Upside
Lowest Forecast
Price Target
101 TWD
35% Upside
Average Forecast
Price Target
102 TWD
36% Upside
Highest Forecast
Price Target
105 TWD
40% Upside
Handa Pharmaceuticals Inc Competitors:
Price Targets
FRAF
Franklin Financial Services Corp
5% Upside
FCNCA
First Citizens BancShares Inc (Delaware)
9% Upside
MAT
Mattel Inc
32% Upside
FRAF
Franklin Financial Services Corp
5% Upside
FCNCA
First Citizens BancShares Inc (Delaware)
9% Upside
MAT
Mattel Inc
32% Upside

Revenue
Forecast

N/A
Past Growth
34% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
34% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

The compound annual growth rate for Revenue over the next 2 years is 34%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Handa Pharmaceuticals Inc

Operating Income
Forecast

N/A
Past Growth
59% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
59% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

The compound annual growth rate for Operating Income over the next 2 years is 59%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Handa Pharmaceuticals Inc

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Net Income Forecast
is not available for Handa Pharmaceuticals Inc

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is Handa Pharmaceuticals Inc's stock price target?
Price Target
102 TWD

According to Wall Street analysts, the average 1-year price target for Handa Pharmaceuticals Inc is 102 TWD with a low forecast of 101 TWD and a high forecast of 105 TWD.

What is the Revenue forecast for Handa Pharmaceuticals Inc?
Projected CAGR
34%

The compound annual growth rate for Revenue over the next 2 years is 34%.

What is the Operating Income forecast for Handa Pharmaceuticals Inc?
Projected CAGR
59%

The compound annual growth rate for Operating Income over the next 2 years is 59%.

Back to Top
ALPHA SPREAD
Follow us
Join 354,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett